These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18035097)

  • 1. Cost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosis.
    Reynolds MR; Pinto DS; Shi C; Walczak J; Berezin R; Holmes DR; Cohen DJ
    Am Heart J; 2007 Dec; 154(6):1221-7. PubMed ID: 18035097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
    Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial.
    Holmes DR; Teirstein P; Satler L; Sketch M; O'Malley J; Popma JJ; Kuntz RE; Fitzgerald PJ; Wang H; Caramanica E; Cohen SA;
    JAMA; 2006 Mar; 295(11):1264-73. PubMed ID: 16531619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
    Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
    Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial.
    Alli OO; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA; Holmes DR;
    Am Heart J; 2012 Mar; 163(3):438-45. PubMed ID: 22424015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction: insights from the TYPHOON trial.
    Canoui-Poitrine F; Jeanblanc G; Alberti C; Armoogum P; Cebrian A; Carrié D; Henry P; Teiger E; Slama M; Spaulding C; Durand-Zaleski I
    Appl Health Econ Health Policy; 2009; 7(1):19-29. PubMed ID: 19558192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry.
    Ong AT; Daemen J; van Hout BA; Lemos PA; Bosch JL; van Domburg RT; Serruys PW
    Eur Heart J; 2006 Dec; 27(24):2996-3003. PubMed ID: 17114234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: an analysis from the C-SIRIUS trial.
    Rinfret S; Cohen DJ; Tahami Monfared AA; Lelorier J; Mireault J; Schampaert E
    Am J Cardiovasc Drugs; 2006; 6(3):159-68. PubMed ID: 16780389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
    Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of sirolimus-eluting stents in percutaneous coronary interventions in Brazil.
    Polanczyk CA; Wainstein MV; Ribeiro JP
    Arq Bras Cardiol; 2007 Apr; 88(4):464-74. PubMed ID: 17546279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Alfonso F; Pérez-Vizcayno MJ; Hernández R; Bethencourt A; Martí V; López-Mínguez JR; Angel J; Iñiguez A; Morís C; Cequier A; Sabaté M; Escaned J; Jiménez-Quevedo P; Bañuelos C; Suárez A; Macaya C;
    J Am Coll Cardiol; 2008 Nov; 52(20):1621-7. PubMed ID: 18992651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents.
    Chevalier B; Moulichon R; Teiger E; Brunel P; Metzger JP; Pansieri M; Carrie D; Stoll HP; Wittebols K; Spaulding C; Fajadet J;
    J Interv Cardiol; 2012 Dec; 25(6):586-95. PubMed ID: 22994863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated sirolimus-eluting stent implantation to treat sirolimus-eluting stent and bare-metal stent restenosis.
    Nishihira K; Shibata Y; Ishikawa T; Nomura K; Nakama T; Mine D; Inoue Y; Ashikaga K; Kuriyama N; Matsuyama A; Imamura T; Asada Y; Kitamura K
    Circ J; 2010 Nov; 74(11):2329-33. PubMed ID: 20890050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
    Kastrati A; Mehilli J; von Beckerath N; Dibra A; Hausleiter J; Pache J; Schühlen H; Schmitt C; Dirschinger J; Schömig A;
    JAMA; 2005 Jan; 293(2):165-71. PubMed ID: 15644543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiographic and clinical outcome for the treatment of in-stent restenosis with sirolimus-eluting stent compared to vascular brachytherapy.
    Pohl T; Kupatt C; Steinbeck G; Boekstegers P
    Z Kardiol; 2005 Jun; 94(6):405-10. PubMed ID: 15940441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes.
    Lemos PA; van Mieghem CA; Arampatzis CA; Hoye A; Ong AT; McFadden E; Sianos G; van der Giessen WJ; de Feyter PJ; van Domburg RT; Serruys PW
    Circulation; 2004 Jun; 109(21):2500-2. PubMed ID: 15148279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
    Stone GW; Ellis SG; O'Shaughnessy CD; Martin SL; Satler L; McGarry T; Turco MA; Kereiakes DJ; Kelley L; Popma JJ; Russell ME;
    JAMA; 2006 Mar; 295(11):1253-63. PubMed ID: 16531618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison with conventional therapies of repeated sirolimus-eluting stent implantation for the treatment of drug-eluting coronary stent restenosis.
    Kim YH; Lee BK; Park DW; Park KH; Choi BR; Lee CW; Hong MK; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2006 Dec; 98(11):1451-4. PubMed ID: 17126648
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.